Shine Technologies products

SHINE Technologies’ production process results in molybdenum-99 that is of high quality and high purity, resulting in Mo-99 that has high specific activity and is ready for delivery to our medical customers. We believe our production of Mo-99 in the United States will contribute to the reliability of SHINE’s supply in a time of chronic shortages of medical isotopes.

SHINE Technologies’ isotope production process is enabling treatment options that have the potential to improve outcomes for patients being treated for a range of cancers, such as prostate cancer. SHINE’s current focus includes production of non-carrier-added lutetium-177. The unique advantages of our n.c.a. Lu-177 production process include an exclusive processing technology, flexibility for irradiation, stable isotope enrichment capability, fewer logistical challenges in transport, and a cleaner and safer production method.